Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Manufacturing meetup
March 2020
SHARING OPTIONS:

BERLIN & UTRECHT, The Netherlands—ProBioGen AG and Lava Therapeutics B.V. are teaming up, having recently closed a cell line development and manufacturing agreement for the latter company’s novel bispecific antibody lead candidate. Per the agreement, ProBioGen will use its CHO.RiGHT expansion platform to conduct cell line development of a γδ T cell-engaging bispecific antibody format. ProBioGen’s platform includes its DirectedLuck Transposase technology, which supports the development of stable, high-titer cell lines. Financial details were not disclosed. Steve Hurly, CEO at Lava Therapeutics, remarked that “Solving the manufacturing requirements early in drug development is a key element to enabling the future success of a program. With ProBioGen, we found a scientific-driven partner with a proven development platform and a dedicated analytical panel for challenging bispecific antibody formats.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.